Compare ALK & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALK | GRFS |
|---|---|---|
| Founded | 1932 | 1940 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.2B |
| IPO Year | N/A | N/A |
| Metric | ALK | GRFS |
|---|---|---|
| Price | $57.54 | $9.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 2 |
| Target Price | ★ $70.91 | $10.15 |
| AVG Volume (30 Days) | ★ 4.0M | 438.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.49% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.71 | $5.47 |
| Revenue Next Year | $6.00 | $4.92 |
| P/E Ratio | $68.77 | ★ $18.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.63 | $6.19 |
| 52 Week High | $78.08 | $11.14 |
| Indicator | ALK | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 57.30 |
| Support Level | $54.41 | $9.07 |
| Resistance Level | $60.50 | $9.64 |
| Average True Range (ATR) | 2.74 | 0.22 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 70.51 | 82.30 |
Alaska Air Group Inc operates two airlines, Alaska and Horizon in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico, and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements (CPA). The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary and Mileage Plan passenger revenue.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.